GLP-1 Microdosing and Migraine: Intracranial Pressure, Headache Days, and What the Liraglutide and Exenatide Studies Found
In a small Italian study, people with stubborn migraine had about half as many headache days after 12 weeks on liraglutide, while their weight barely moved. The explanation researchers keep returning to is the fluid around the brain, and how GLP-1 receptors control how much of it gets made.
19.8 → 10.7
MONTHLY HEADACHE DAYS BEFORE AND AFTER LIRAGLUTIDE IN A 31-PERSON MIGRAINE PILOT (2025)
5.7
CMCSF DROP IN BRAIN FLUID PRESSURE 2.5 HOURS AFTER EXENATIDE IN THE IIH:PRESSURE TRIAL
7%
FALL IN TRIPTAN USE A YEAR AFTER 189,392 DANES STARTED SEMAGLUTIDE (2026)
Consider a teacher in her mid-forties who has had migraine since her twenties. She now loses more than half of each month to headache, has tried two preventive drugs without much change, and keeps a triptan in every bag she owns. When her prescriber mentions a low-dose GLP-1 protocol for weight, her first question has nothing to do with the scale. She has read that these drugs might help migraine and wants to know if that is real.
The honest answer is that a signal exists, and it is more interesting than a simple weight story. This article walks through why weight and migraine are linked, the pressure mechanism, the one prospective migraine study, the much larger body of work in a related pressure disorder, the registry data on triptan use, and what all of that does and does not say about microdosing. The teacher is a composite example, not a real patient.
Key takeaways
- •In a 2025 open-label pilot, liraglutide 1.2 mg daily cut monthly headache days from 19.8 to 10.7 over 12 weeks in 31 people with obesity and treatment-resistant migraine, with no meaningful change in BMI.
- •In the randomized IIH:Pressure trial, exenatide lowered intracranial pressure by 5.7 cmCSF within 2.5 hours, far too fast to be explained by weight loss.
- •Rat studies show GLP-1 receptors in the choroid plexus slow the pump that drives cerebrospinal fluid secretion, which is the leading explanation for the pressure effect.
- •A 2026 Danish registry study of 189,392 semaglutide starters found triptan use fell by 7 percent at 12 months, with the change seen in women but not men.
- •No randomized placebo-controlled trial has tested a GLP-1 drug for migraine prevention, and no study has tested a GLP-1 microdose for any headache disorder.
Is obesity linked to migraine?
Obesity is linked to a modestly higher risk of migraine. A 2017 meta-analysis in Neurology by Bizu Gelaye and colleagues pooled 12 studies with 288,981 participants and found that people with obesity had a 27 percent higher age- and sex-adjusted risk of migraine than people of normal weight. Underweight people also had a higher risk, at 13 percent, while the small rise for overweight lost significance after further adjustment.
Odds of migraine compared with normal weight
Gelaye B et al., Neurology 2017 (meta-analysis, 12 studies, 288,981 participants). Age- and sex-adjusted odds ratios.
An odds ratio above 1 means higher odds than people of normal weight. These are associations from observational studies.
A 27 percent rise in risk is real but not dramatic, and the U-shaped pattern matters. If extra weight alone drove migraine, being underweight would not also raise the odds. Gelaye's group concluded that studies were still needed to show whether changing weight changes migraine. That open question is where GLP-1 drugs have stepped in, and the early data suggest weight may not be the main route at all.
How could a GLP-1 drug change pressure inside the skull?
A GLP-1 drug could change pressure inside the skull by slowing how much cerebrospinal fluid the brain produces. Cerebrospinal fluid is made mainly by the choroid plexus, a tissue lining the brain's ventricles. In 2017, Hannah Botfield and colleagues reported in Science Translational Medicine that choroid plexus cells carry GLP-1 receptors, and that activating them with exendin-4 reduced the activity of the sodium-potassium pump that drives fluid secretion.
In rats with raised pressure from hydrocephalus, the same drug lowered intracranial pressure, and blocking the GLP-1 receptor stopped the effect. Exendin-4 is the research name for exenatide, a GLP-1 drug already used in type 2 diabetes. Rat findings are mechanism evidence only, but this one gave researchers a specific, testable reason to try the drug in people.
The link to migraine comes from the clinic. The Braca team noted that chronic migraine and intracranial hypertension without optic nerve swelling can look almost the same at the bedside, which has led some headache specialists to suspect that subtle pressure problems contribute to some chronic migraine. That remains a hypothesis. The GLP-1 studies are one of the first practical ways to test it.
What did the liraglutide migraine study find?
The liraglutide migraine study found that headache days roughly halved over 12 weeks without meaningful weight loss. Simone Braca and colleagues at the University of Naples Federico II published the prospective pilot in Headache in 2025. They enrolled 31 adults with a BMI above 30 and high-frequency or chronic migraine that had not responded to at least two preventive treatments, and added liraglutide 1.2 mg daily to their existing care.
Mean monthly headache days
Braca S et al., Headache 2025 (open-label pilot, n=31, liraglutide 1.2 mg daily for 12 weeks).
No placebo group. Open-label studies in migraine tend to overstate benefit because expectation and regression to the mean both lower headache counts.
Mean monthly headache days fell from 19.8 to 10.7, a difference of 9.1 days. Mean BMI went from 34.0 to 33.9, a change that was not statistically significant, and the size of each person's BMI change did not predict the size of their headache improvement. Age, sex, and other medications did not explain the result either.
Three cautions apply. The study had no control arm, so some of the drop would likely have happened anyway. It was small. And two of the authors reported speaking fees from Eli Lilly, a maker of GLP-1 drugs. A 2026 case series from Tulsi Shah and colleagues described two people with migraine who improved on tirzepatide, but both also lost weight, which the authors flagged as a major confounder. Neither report proves the drug works for migraine. Together they justify a proper trial.
What happened to brain pressure in the exenatide trial?
Brain pressure fell within hours of exenatide in the IIH:Pressure trial, the only randomized, placebo-controlled study to measure the effect directly. James Mitchell, Alexandra Sinclair, and colleagues at the University of Birmingham published it in Brain in 2023. They recruited 16 women with active idiopathic intracranial hypertension, a disorder of raised fluid pressure around the brain, and fitted them with telemetric monitors that recorded pressure continuously.
Fall in intracranial pressure on exenatide (cmCSF)
Mitchell JL et al., Brain 2023 (IIH:Pressure, randomized, placebo-controlled, 15 of 16 women completed).
Mean starting pressure was 30.6 cmCSF. The trial set its significance threshold at 0.1 because it was a small early-phase study.
Exenatide lowered pressure by 5.7 cmCSF at 2.5 hours, 6.4 at 24 hours, and 5.6 at 12 weeks. The women had a mean BMI of 38.1 and a starting pressure of 30.6 cmCSF. The 2.5-hour result is the important one for anyone thinking about mechanism, because no meaningful weight loss can happen in an afternoon. No serious safety signals were reported.
For scale, the IIH Weight Trial by Susan Mollan and colleagues, published in JAMA Neurology in 2021, randomized 66 women with IIH to bariatric surgery or a community weight programme. Surgery produced weight 21.4 kg lower at 12 months and pressure 6.0 cmCSF lower than the weight programme. Exenatide reached a similar pressure drop in hours, with no comparable weight change.
An exploratory analysis by Olivia Grech and colleagues in Eye in 2024 checked whether the drug affected thinking, since older pressure-lowering drugs can dull cognition. Scores did not worsen compared with placebo, and the exenatide group improved from baseline on several tests.
Cognitive T-scores in the exenatide group
Grech O et al., Eye 2024 (IIH:Pressure substudy, exenatide n=7). A T-score of 50 is the population average.
- Baseline
- 12 weeks
Seven people is a very small group, and repeat testing alone tends to raise scores. The main finding is that cognition did not get worse.
What do larger studies show in intracranial hypertension?
Larger studies in intracranial hypertension show consistently fewer headaches and less optic nerve swelling in GLP-1 users, though most of the data are observational. A 2026 meta-analysis in Headache by Lucas Falcão and colleagues pooled eight studies covering 13,243 patients. GLP-1 users had lower risk of papilledema, frequent headache, and visual disturbance at 3 months, and the benefit held at 24 months.
Risk ratio vs control in IIH, GLP-1 receptor agonists
Falcão L et al., Headache 2026 (meta-analysis, 8 studies, 13,243 patients). Rounded.
- 3 months
- 24 months
A risk ratio below 1 means the outcome was less common in GLP-1 users. The authors rated the evidence as low certainty because most studies were observational.
The authors were blunt about the limits. They described the evidence base as dominated by observational studies with moderate to serious risk of confounding, and called the results hypothesis-generating. An earlier 2025 meta-analysis by Maria-Ioanna Stefanou and colleagues in the European Journal of Neurology, covering 1550 patients, found that GLP-1 drugs reduced monthly headache days by 3.64 at 3 months. It also found mild gastrointestinal effects or nausea in 88 percent of treated patients.
A 2026 Johns Hopkins analysis of 3185 people with IIH and a BMI of 40 or more compared GLP-1 drugs with bariatric surgery. Surgery gave faster early improvement, but outcomes were comparable after 18 months, and GLP-1 users had more nausea and vomiting. For IIH, GLP-1 drugs are now a serious research option. For migraine, the IIH work supplies the mechanism and the safety experience, not proof.
Do people on semaglutide use fewer migraine medicines?
People on semaglutide used slightly fewer migraine medicines in a large Danish registry study. Nora Roland and colleagues at the University of Southern Denmark tracked all 189,392 adults who started semaglutide for weight management in Denmark between December 2022 and December 2024, and published the results in the Journal of Headache and Pain in 2026. Triptan use had been rising before people started semaglutide, then reversed, ending 7 percent lower at 12 months.
Triptan use 12 months after starting semaglutide, rate ratio
Roland N et al., Journal of Headache and Pain 2026 (Danish nationwide registry, 189,392 adults).
Men showed no statistically significant change. Two study authors are Novo Nordisk employees.
The fall came mostly from existing triptan users taking fewer doses, not from fewer people starting triptans. The largest drops were in people aged 18 to 35 and in people who had previously used migraine prevention drugs. Women showed an 8 percent reduction, which fits the fact that migraine is far more common in women. A 7 percent change is modest. It is also a population average that includes many people without migraine, so the effect in people with frequent attacks could be larger or smaller.
Can GLP-1 drugs also cause headaches?
GLP-1 drugs can also cause headaches, which makes the migraine picture two-sided. A 2025 review by Ferreira and colleagues in Arquivos de Neuro-Psiquiatria described GLP-1 drugs as potentially therapeutic for some headache disorders while listing headache as a possible side effect. Early-treatment headaches are often tied to drinking less, eating far less, skipped meals, or a dose increase.
For someone with migraine, the first weeks on any GLP-1 dose can be harder to read. Skipped meals and dehydration are classic migraine triggers, and reduced appetite makes both more likely. Steady fluids, regular small meals with protein, and a headache diary that records dose days help separate a side effect from the underlying pattern. Our guide to headaches, dizziness and blood pressure covers the side-effect side in more detail.
What does this mean for GLP-1 microdosing?
For GLP-1 microdosing, the migraine research is intriguing but untested. Every study described here used standard doses in people with obesity, and none tested low or slowly titrated doses. Two findings explain why the question keeps coming up: exenatide lowered brain pressure within 2.5 hours, and liraglutide reduced headache days without moving BMI. Both point to an effect that does not depend on large weight loss, which is exactly what microdose protocols avoid chasing.
Whether that effect needs a full dose is unknown. Pressure and appetite effects could have different dose thresholds, and nobody has measured where the pressure effect starts. Anyone with migraine who is starting a GLP-1 at any dose is better served by tracking than by expectation. A simple diary of headache days, triptan doses, sleep, meals, and injection days gives a real before-and-after picture after two or three months.
Some symptoms need a doctor rather than a diary. A new type of headache, a headache that is worse lying down or on waking, pulsing noises in the ears, or any change in vision can signal raised pressure or another problem and should be assessed promptly. Our article on eye health and vision covers the optic nerve questions that sometimes come up with GLP-1 drugs.
What is the takeaway?
The takeaway is that GLP-1 drugs lower intracranial pressure in people, with randomized evidence in IIH, and that early migraine data hint at fewer headache days through a route that may not depend on weight. Migraine prevention with these drugs has not been proven, and microdosing has not been studied at all. For the teacher, a reasonable plan is to keep her current migraine care, start any GLP-1 under supervision, protect fluids and meals in the first weeks, and let three months of diary entries show what changed.
"The pressure fell before the weight could. That is the part worth testing."
Frequently asked questions
Can GLP-1 drugs help with migraine?
GLP-1 drugs may reduce migraine frequency in some people, but the evidence is early. A 2025 open-label pilot study by Braca and colleagues gave liraglutide 1.2 mg daily to 31 people with obesity and hard-to-treat migraine, and monthly headache days fell from 19.8 to 10.7 over 12 weeks. There was no placebo group, so a randomized trial is needed before anyone can say the drug caused the improvement.
Why would a weight-loss drug affect headaches?
GLP-1 drugs appear to affect headaches through cerebrospinal fluid rather than through weight alone. In a 2017 rat study, Botfield and colleagues showed that GLP-1 receptors in the choroid plexus, the tissue that makes cerebrospinal fluid, reduce the activity of a pump that drives fluid secretion when activated. Less fluid production means lower pressure inside the skull, and raised pressure is one suspected contributor to some chronic headaches.
What is idiopathic intracranial hypertension?
Idiopathic intracranial hypertension, or IIH, is a condition in which the pressure of the fluid around the brain is too high without a tumour or other clear cause. It mostly affects women of reproductive age with obesity, and it causes daily headaches and swelling of the optic nerve called papilledema, which can threaten vision. Weight loss is a core part of treatment, which is why GLP-1 drugs are being studied for it.
Did exenatide lower brain pressure in a real trial?
Exenatide lowered intracranial pressure in the IIH:Pressure randomized trial published in Brain in 2023. Sixteen women with active IIH had pressure monitors implanted, and exenatide lowered pressure by 5.7 cmCSF at 2.5 hours, 6.4 at 24 hours, and 5.6 at 12 weeks compared with placebo. The drop at 2.5 hours came long before any weight could have changed.
Does the migraine benefit depend on losing weight?
The migraine benefit did not track weight loss in the one prospective migraine study. In the Braca pilot, BMI moved from 34.0 to 33.9, which was not a meaningful change, yet headache days roughly halved, and BMI change did not predict headache change. That pattern is part of why researchers suspect a direct effect on pressure or pain signalling rather than an effect of weight.
Do people on semaglutide use fewer migraine drugs?
People who started semaglutide for weight management in Denmark used somewhat fewer triptans afterwards. A 2026 registry study of 189,392 adults found triptan use fell by 7 percent at 12 months, by 8 percent in women, and showed no clear change in men. This is observational data, so it cannot separate the drug from weight loss, lifestyle changes, or who chooses to start treatment.
Can GLP-1 drugs cause headaches instead?
GLP-1 drugs can also cause headaches, usually early in treatment or after a dose increase. These headaches are often linked to dehydration, eating much less, or lower blood sugar between meals, and they tend to ease as the body adjusts. A headache that is new, severe, or comes with vision changes needs a medical review rather than an assumption that it is a side effect.
Has GLP-1 microdosing been tested for migraine?
No study has tested a GLP-1 microdose for migraine or intracranial pressure. The trials used standard drug doses, such as liraglutide 1.2 mg daily or exenatide at study doses, in people with obesity. The finding that pressure fell within hours, and that headache days fell without weight loss, raises the question of whether lower doses could have a similar effect, but that idea has not been studied.
Clinical references
- Braca S, Russo CV, Stornaiuolo A, et al. Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: a prospective pilot study. Headache. 2025. doi:10.1111/head.14991
- Mitchell JL, Lyons HS, Walker JK, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023. doi:10.1093/brain/awad003
- Grech O, Mitchell JL, Lyons HS, et al. Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in idiopathic intracranial hypertension. Eye. 2024. doi:10.1038/s41433-023-02908-y
- Botfield HF, Uldall MS, Westgate CSJ, et al. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Science Translational Medicine. 2017. doi:10.1126/scitranslmed.aan0972
- Falcão L, Brenner LBO, Machado Magalhães PL, et al. Glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: a systematic review and meta-analysis. Headache. 2026. doi:10.1111/head.70131
- Stefanou MI, Chatziralli I, Lambadiari V, et al. Efficacy and safety of GLP-1 and dual GIP/GLP-1 receptor agonists in idiopathic intracranial hypertension: a systematic review and meta-analysis. European Journal of Neurology. 2025. doi:10.1111/ene.70358
- Roland N, Sonne H, Pellesi L, et al. Impact of semaglutide introduction on the use of triptans: an interrupted-time series. Journal of Headache and Pain. 2026. doi:10.1186/s10194-026-02462-4
- Shah T, Dougherty C, Ailani J, Kerrigan T. Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: a case series. Headache. 2026. doi:10.1111/head.70152
- Mollan SP, Mitchell JL, Ottridge RS, et al. Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension: a randomized clinical trial. JAMA Neurology. 2021. doi:10.1001/jamaneurol.2021.0659
- Maroufi SF, Um RS, Theodore JN, et al. Bariatric surgery versus GLP-1RAs in idiopathic intracranial hypertension: a propensity matched multi-institutional cohort. Neurosurgery. 2026. doi:10.1227/neu.0000000000004099
- Gelaye B, Sacco S, Brown WJ, et al. Body composition status and the risk of migraine: a meta-analysis. Neurology. 2017. doi:10.1212/WNL.0000000000003919
- Halloum W, Dughem YA, Beier D, Pellesi L. Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review. Journal of Headache and Pain. 2024. doi:10.1186/s10194-024-01821-3
Medical disclaimer. This article is for general educational and informational purposes only. It is not medical advice and not a substitute for the neurologist, headache specialist, prescriber, or clinician responsible for your care. GLP-1 medications have not been shown in randomized trials to prevent migraine, and the migraine findings described here come from small open-label, case-series, and registry studies that cannot prove cause and effect. Charts show values reported in the cited studies, and the patient described in this article is a composite example rather than a real person. GLP-1 microdosing is an off-label approach that has not been studied for headache disorders and should only be undertaken under a prescriber's supervision. Do not stop or change any migraine medication on the basis of this article. A sudden severe headache, a new pattern of headache, headache with vision changes, weakness, confusion, or fever requires prompt or urgent medical care.